Research and development (R&D) plays an integral role in the success of pharmaceutical firms. According to a study conducted by Booz & Co, the healthcare industry had R&D expenditures of over $111 billion in 2009. Based on evidence provided in the report, of the 10 most research-intensive firms in the world, six are in the healthcare industry.

IN PICTURES: 5 Tips To Reading The Balance Sheet

The Tech Factor
Not surprisingly, tech-based firms such as Nokia (NYSE:NOK) and IBM (NYSE:IBM) cumulatively devoted the most resources to research and development, while the auto industry, which is pushing to rebrand its image to one of a more environmentally friendly business, came in third. Computing/electronics and autos had 2009 R&D expenditures of $146.7 and $85.2 billion respectively.

R&D in Healthcare
After analyzing R&D spending of the world's 1,000 top innovation-driven companies, Booz & Co. revealed that 2009 spending decreased by an average 3.5%. Although most of the declines were attributed to the auto industry, many American healthcare firms saw cutbacks as well.

Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ), which ranked in the five and seven spots on the list, saw year-over-year outlays decrease by 2.6% and 7.8% respectively.

Expiring Patents
However, with improving economic conditions, major pharmaceuticals are forced to renew their focus on R&D spending. As numerous major drugs such as Pfizer's Lipitor and GlaxoSmithKline's (NYSE:GSK) Advair lose their patents, generic drug makers will enter the market and begin to mass produce these medications. The best-selling cholesterol drug, Lipitor, contributed $8.1 billion to Pfizer's top line as of the first nine months of 2010. In fact, Lipitor sales contribute approximate 16.1% to Pfizer's total year to date revenue. Xalatan, another drug with an expiring patent in 2011 produced third-quarter sales of $416 million.

Competition
Israel's generic pharmaceutical giant, Teva (Nasdaq:TEVA), is set to capitalize on the growing list of patents set to expire in upcoming years. A major advantage for generic drug manufacturers is that they can allocate fewer resources to R&D. For example, Teva's nine-month R&D-to-sales ratio sits at 5.7%, compared to Pfizer's 13.1%.

In its latest quarter, Teva's North American sales increased by 22%, largely driven by a generic version of Pfizer's antidepressant, Effexor.

The major drug companies have two primary alternatives to maintain revenue growth: boost R&D spending and/or acquire competitors with drugs in the pipeline, which can replace the sales lost to generic brands. The major drug companies have been utilizing both approaches.

Merck (NYSE:MRK) increased its third-quarter research and development expense by 77%, spending $2.3 billion compared to $1.3 billion in 2009. Likewise, Pfizer's R&D spending surged from $1.63 billion to $2.19 billion. Furthermore, both of these corporations have been involved in large acquisitions with Merck purchasing Millipore for $7 billion. Pfizer is acquiring Wyeth for $68 billion.

The Bottom Line
Research and development spending is a crucial component of the pharmaceutical industry, as drug companies cannot rely on previously-developed technology to drive profits indefinitely. With many major patents expiring in 2011, companies will be forced to find alternative revenue streams. (Investors take note: companies that cut research and development are in danger of saving today but losing big tomorrow. Check out Buying Into Corporate Research & Development.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!